Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 05 2025
0mins
Source: Newsfilter
Clinical Trial Expansion: Estrella Immunopharma has activated a second clinical site at Baylor Research Institute for its STARLIGHT-1 Phase I/II trial of EB103, a CD19-Redirected ARTEMIS® T-cell therapy aimed at treating relapsed or refractory B-cell non-Hodgkin's lymphoma.
Therapeutic Approach: EB103 utilizes innovative ARTEMIS® technology to target and destroy CD19-positive cancer cells, representing a potential advancement in safer and more effective treatments for patients with advanced NHL.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ESLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ESLA
About ESLA
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Estrella Immunopharma Closes $8 Million Financing to Advance Clinical Trials
- Successful Financing: Estrella Immunopharma has closed a registered direct offering with a single healthcare-focused institutional investor, issuing 4,063,290 shares of common stock and 1,000,000 pre-funded warrants, raising approximately $8 million, which enhances the company's financial resources for clinical development.
- Advancing Product Development: The proceeds will support the Phase II clinical trial of Estrella's lead product candidate, EB103, aimed at providing new treatment options for patients with cancers and autoimmune diseases who are not eligible for existing therapies, highlighting its significant clinical value.
- Investor Confidence: The CEO stated that this financing underscores continued investor support for the company's clinical vision, indicating strong market confidence in Estrella's future growth, which may facilitate further advancements in the biopharmaceutical sector.
- Compliance and Transparency: The financing adheres to SEC registration requirements, ensuring compliance in all securities transactions, while the company commits to filing registration statements with the SEC, thereby enhancing investor trust in the company's transparency.
Continue Reading
Estrella Immunopharma Closes $8 Million Financing to Advance Clinical Trials
- Successful Financing: Estrella Immunopharma closed a registered direct offering with a single healthcare-focused institutional investor, raising approximately $8 million by issuing 4,063,290 shares of common stock and 1,000,000 pre-funded warrants, thereby strengthening its financial position to support clinical objectives.
- Advancing Clinical Programs: The financing will provide Estrella with the necessary resources to advance its lead product EB103 into Phase II clinical trials, aimed at offering treatment options for cancer patients who are ineligible for currently marketed therapies, which holds significant market potential.
- Investor Confidence: The CEO stated that this financing underscores continued investor support for the company's clinical vision, indicating market recognition of its ARTEMIS T-cell therapies, which may enhance future fundraising capabilities.
- Compliance Assurance: The offering was conducted under SEC registration statements, ensuring compliance, and through a registration rights agreement with the investor, Estrella will file registration statements to cover the resale of common stock, thereby boosting investor confidence.
Continue Reading